Venetoclax after idelalisib: relevant progress for CLL
- PMID: 29650729
- DOI: 10.1182/blood-2018-02-826396
Venetoclax after idelalisib: relevant progress for CLL
Conflict of interest statement
Conflict-of-interest disclosure: F.B. received research support from Roche, Gilead, Janssen, Celgene, Novartis, AbbVie, and Takeda; and honoraria from Roche, Gilead, Janssen, Celgene, AbbVie, and Takeda. M.H. received research support from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and AbbVie; and honoraria from Roche, Gilead, Mundipharma, Janssen, Celgene, Pharmacyclics, and AbbVie.
Comment on
-
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.Blood. 2018 Apr 12;131(15):1704-1711. doi: 10.1182/blood-2017-06-788133. Epub 2018 Jan 5. Blood. 2018. PMID: 29305552 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources